CN103772491B - Nf-KB peptide inhibitor 3 and application thereof - Google Patents

Abstract

Nf-KB peptide inhibitor 3 and application thereof, the present invention relates to pharmaceutical field, be specifically related to have suppression nf-KB, the polypeptide of energy prevention and therapy rheumatoid arthritis.Its sequence is TRILAQHRLYINNSGGE is brand-new sequence, and useful benefit of the present invention can be used for treating rheumatoid arthritis, has potential new drug development value.

Description

Nf-KB peptide inhibitor 3 and application thereof

technical field:

The present invention relates to pharmaceutical field, be specifically related to the nf-KB peptide inhibitor for prevention and therapy or prevention rheumatoid arthritis.

background technology:

Rheumatoid arthritis (rheumatoid arthritis, RA) is one of clinical modal inflammatory arthropathy and main disability-causing factor.Be about 0.5%-1.0% in the whole world, the morbidity of RA is about 0.4% in China.RA can betide any age, and with advancing age, sickness rate also increases thereupon.Women the age occurred frequently be 45-55 year, sex and RA onset relation are close, and the ratio of men and women is about 1:3.RA is the chronic systemic inflammation disease that a kind of cause of disease not yet understands, for main clinical manifestation, belongs to autoimmune inflammatory disease with pathology outside chronic, symmetry, many synovial joints inflammation and joint.Patient often with hand or wrist pain and swelling (particularly the swelling at wrist back), for onset symptoms, do not alleviate by Symptoms last, though common symptomatic treatment can relief of symptoms, usually because medication is irregular or in shortage and cause symptom repeatedly.Can occur during disease progression that obvious morning stiff, usually can reach more than 1 hour, and constantly increase the weight of; There is certain joint function disturbance simultaneously.

The cause of disease of rheumatoid arthritis and pathogenesis are not yet completely clear, and its basic pathology feature is vasculitis and synovitis.Intraarticular synovial membrane blood vessel hyperplasia, forms pannus, causes synovial membrane to thicken, ooze out and increase, and secretion cytokine profiles, invades cartilage and cause bone damage.All erodables are organized also to the flesh chamber around it, ligament, stndon sheath and muscle etc., thus affects the stable of joint, easily joint deformity occur and occur dysfunction.Vasculitis also can invade each organs and tissues in the whole body, forms systemic disease.

The medicine of current treatment RA is divided into two large classes: control symptom medicine and control disease medicine.Due to RA etiology unknown, therefore there is no the medicine that can be rated as and control disease now.The antirheumatic controlling symptom is divided into four classes: one, non-steroidal anti-inflammatory drugs, and be commonly referred to a line medicine, this kind of medicament categories is various, nearly tens of kinds, domestic market.Two, steroid hormone, hormone is an extraordinary pain stop and anti-inflammation medicine, but is used alone for a long time and can not improves the state of an illness, bring many side effects on the contrary, transitionality before hormone does medication onset slowly as two wires is with being fine, but consumption is little, and the time is unsuitable long.Heavier in the state of an illness, with the patient of extra-articular manifestation, short impacts, and necessary when combining two wires medicine treatment.Three, act on antirheumatic slowly, be commonly referred to two wires medicine, so-called slow effect cartridge bag draws together antimalarial drug, golden salt, Trolovol and willow nitrogen sulfapyridine, and their treatment RA onsets are slow, and long term has certain mitigation to the RA state of an illness, therefore feelings of also pretending illness improve medicine.Four, immunosuppressor: conventional have Rheumatrex, endoxan, azathioprine, trypterygine, Stem of Orientoine etc.

Nf-KB is that one is extensively present in intracellular nuclear factor, and with the generation of inflammation in sacroiliitis, cartilage injury, the formation of cell migration and pannus has important relation.With nf-KB for action target spot, the new way of the diseases such as treatment of arthritis may be become.Non-steroidal anti-inflammatory drugs, glucocorticosteroid, glycosaminoglycan and Novel protease body inhibitor etc. find the activation that all can suppress nf-KB.In addition, nf-KB decoy ODN and siRNA interference treatment also achieve gratifying achievements.However, the nf-KB peptide inhibitor of unripe exploitation comes out, and is used for the treatment of RA.

summary of the invention:

The present invention seeks to the feature for existing nf-KB antagonist, design the nf-KB polypeptide antagonist that a kind of molecular weight is little, can avoid producing antigen-reactive, be more applicable for clinical application.

Technical solution of the present invention is to provide a kind of nf-KB peptide inhibitor 3, and its sequence is TRILAQHRLYINNSGGE, and the application in treatment or prevention medicine for treating rheumatoid arthritis.

beneficial outcomes:

Nf-KB peptide inhibitor 3 sequence TRILAQHRLYINNSGGE in the present invention, can targeted inhibition nf-KB, and the physiology suppressing nf-KB acceptor to produce or the effect of pathology, reach the effect of prevention or treatment rheumatoid arthritis.

Through great many of experiments, contriver knows that nf-KB peptide inhibitor 3 can suppress the development of adjuvant type rat kind rheumatic arthritis and DBA/1 mouse collagen type rheumatoid arthritis, experiment in vivo proves to have the arthritic effect of significant treatment similar rheumatism type, and few side effects, the few cost of consumption reduces.Illustrate that the nf-KB peptide inhibitor 3 that the present invention designs is scientific, rational, feasible and effective, can as treatment or prevention medicine for treating rheumatoid arthritis.

Embodiment

Embodiment 1

Nf-KB peptide inhibitor 3 is immanoprotection action in collagen-induced mouse arthritis animal model

Build collagen type mouse arthritis animal model, the therapeutic action of research nf-KB peptide inhibitor 3 pairs of mouse collagen Induced Arthritis (collagen induced arthritis, CIA).Adopt mouse as animal subject, SPF level DBA/1 mouse 90 (is provided by Shanghai western pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal productiong ticket number: SCXK (Shanghai) 2008-0016), male, 7-8 week age, body weight is 18-22 g, be divided into 6 groups at random, Normal group respectively, model control group, low middle high 3 the dosage groups (0.4,0.8,1.6 mg/kg) of peptide inhibitor 3 and positive drug control group (methotrexate 2 mg/kg).Except normal group, within the 0th day, each experimental group sets up mouse CIA model, and method is chicken cartilage II Collagen Type VI (c II) becomes 4 mg/ml solution with 0.1 mol/l acetate dissolution, in 4 DEG C of refrigerator overnight.Experimental day is fully emulsified with complete Freund's adjuvant (CFA) equal-volume containing 4 mg/ml Myeobaeterium tuberculosis strain H37Rv with II Collagen Type VI, after DBA/1 mouse anesthesia, often only inject emulsifying agent 50 μ l in its afterbody intracutaneous and carry out sensitization, after fully emulsified with II Collagen Type VI (c II) of 4 mg/ml and incomplete Freund's adjuvant (IFA) equal-volume after 21 d, carry out immunity again with the emulsifying agent of same dose in afterbody.Modeling the 30th d plays subcutaneous administrations: 3 dosage groups (0.4,0.8,1.6 mg/kg) of polypeptide 3: every day twice, continuous 10 days; Positive drug control group (methotrexate 2 mg/kg): every five days once, continuous 3 times; Normal group and model control group (physiological saline): continuous 10 days.Respectively within after modeling the 21st day to the 70th day every 3 days, weighing in, Joint scores, detect left and right metapedes ankle diameter to observe medicine to the arthritic impact of mouse collagen type respectively.

Result: after modeling, mouse is compared with normal mouse, latter 27th day of immunity, CIA mouse foot pawl is red and swollen, and arthritis index scoring is increased, and model group 45-60 days is swelling peak, and model group started body weight from the 35th day to be increased hardly, and also there is decline in the later stage slightly.Nf-KB peptide inhibitor 3 immanoprotection action concrete outcome in collagen-induced mouse arthritis animal model is as follows:

Nf-KB peptide inhibitor 3 is on the impact of the left whole pawl swelling of mouse collagen type sacroiliitis, positive controls, the left back ankle diameter of the high, medium and low dosage group of nf-KB peptide inhibitor 3 compare with model group, all have pole significant difference (P<0.01) experimental result to have statistical significance.Nf-KB peptide inhibitor 3 is on the impact of the right whole pawl swelling of mouse collagen type sacroiliitis, positive controls, the right back ankle diameter of the high, medium and low dosage group of nf-KB peptide inhibitor 3 compare with model group, all have pole significant difference (P<0.01), experimental result has statistical significance.The impact of nf-KB peptide inhibitor 3 on collagen type arthritic mice clinical score, the scoring of polypeptide 3 basic, normal, high dosage group four limbs is significantly lower than model control group (P < 0.01), compare pole significant difference with model control group, experimental result has statistical significance.Nf-KB peptide inhibitor 3 affects collagen type arthritic mice body weight, polypeptide 3 high, medium and low dosage group body weight is significantly higher than model control group (P < 0.01), compare pole significant difference with model control group, experimental result has statistical significance.

Conclusion: nf-KB peptide inhibitor 3 pairs of mouse collagen type sacroiliitis have therapeutic action.

Embodiment 2

Immanoprotection action in nf-KB peptide inhibitor 3 pairs of adjuvant type rat arthritis animal models

Build adjuvant type rat arthritis animal model, the therapeutic action of research nf-KB peptide inhibitor 3 pairs of adjuvant-induced arthritises (Adjuvant arthritis, AA) rat.Adopt rat as animal subject, SPF level SD rat 90 (is provided by Shanghai western pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal productiong ticket number: SCXK (Shanghai) 2008-0016), male, body weight is 140 g-160 g, be divided into 6 groups at random, Normal group respectively, model control group, low middle high 3 the dosage groups (0.2 of nf-KB peptide inhibitor 3,0.4,0.8 mg/kg) and positive drug control group (methotrexate 1 mg/kg).Except normal group, within the 0th day, each experimental group sets up rat AA model, and method is that injection of wasting time fully afterwards in the left side of rat causes experimental animal model of CFA induced adjuvant arthritis in rats containing mycobacterium tuberculosis (H37RA, 10 mg/ml) complete Freund's adjuvant 0.08 ml of deactivation.Modeling plays subcutaneous administrations on the 10th day: 3 dosage groups (0.2,0.4,0.8 mg/kg) of polypeptide 3: every day twice, continuous 10 days; Positive drug control group (methotrexate 1 mg/kg): every five days once, continuous 3 times; Normal group and model control group (physiological saline): continuous 10 days.Respectively at after modeling the 8th, 11,14,17,20,23 and 26 days, weigh in, Joint scores, detect left and right metapedes ankle diameter to observe medicine to the arthritic impact of rat adjuvant type respectively.

Result: after modeling, rat is compared with normal rat, the left back foot of AA rat can produce primary arthritis rapidly, occurs obvious swelling, and with festering; Start to occur post-traumatic arthritis after about 10 d of right back foot, the score value of scoring increases gradually; Ear's blood vessel hyperplasia is obvious simultaneously, obviously red and swollen; There is swelling in caudal articular process.Nf-KB peptide inhibitor 3 is immanoprotection action in adjuvanticity rat arthritis animal model, and concrete outcome is as follows:

Nf-KB peptide inhibitor 3 is on the impact of rat primary sacroiliitis foot pawl swelling, the left back ankle diameter of basic, normal, high dosage group of rat positive controls, nf-KB peptide inhibitor 3 compares with model group, has pole significant difference (P<0.01); The left back ankle diameter of the basic, normal, high dosage group of nf-KB peptide inhibitor 3 compares with model group, and all have significant difference (P<0.05), experimental result has statistical significance.Nf-KB peptide inhibitor 3 is on the impact of rat post-traumatic arthritis foot pawl swelling, rat positive controls, the right back ankle diameter of the basic, normal, high dosage group of nf-KB peptide inhibitor 3 compare with model group, have significant difference (P<0.05).Nf-KB peptide inhibitor 3 is on the impact of adjuvant type rats with arthritis clinical score, the scoring of polypeptide 3 basic, normal, high dosage group four limbs, significantly lower than model control group (P < 0.05), all has statistical significance with model control group comparing difference.Nf-KB peptide inhibitor 3 is on the impact of adjuvant type rats with arthritis body weight, and polypeptide 3 high, medium and low dosage group body weight is significantly higher than model control group (P < 0.05), all has statistical significance with model control group comparing difference.

Conclusion: nf-KB peptide inhibitor 3 pairs of AA rat arthritis have therapeutic action.

SEQUENCE LISTING

<110> Nantong Chengxin Amino Acid Co., Ltd.

<120> nuclear Factor-Kappa B peptide inhibitor 3 and application thereof

<130>

<160> 1

<170> Patent In version 3.3

<210> 1

<211> 17

<212> PRT

<213> artificial sequence

<400> 1

Thr Arg Ile Leu Ala Gln His Arg Leu Tyr Ile Asn Asn Ser Gly Gly Glu

1 5 10 15

 

Claims (1)

1. nf-KB peptide inhibitor 3, is characterized in that its sequence is TRILAQHRLYINNSGGE.